Results 111 to 120 of about 6,983 (156)

Management of Trichodysplasia Spinulosa in a Pediatric Kidney Transplant Patient With Topical Cidofovir and Oral Leflunomide. [PDF]

Pediatr Transplant
Hansen AM, Mehra S, Bowen AR, Sherbotie J, Cipriano SD.   +4 more
europepmc   +1 more source

Antiviral activity of Hellenia speciosa (J. Koenig) S.R. Dutta rhizome metabolites against human adenovirus: insights from molecular docking and in vitro studies. [PDF]

Front Pharmacol
Alnhhas S, Bouback T, Albeshri A, Alsahafi T, Al-Sarraj F, Al-Sulaimany FA, Ali M, Moatasim Y, Kutkat O, Gaballah M, Badierah R, Taibah EO, Almulaiky YQ, Al-Zughaibi F, Mufrrih M, Al-Maaqar SM, Fathuldeen SM.   +16 more
europepmc   +1 more source

Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction. [PDF]

Blood Adv
Rubinstein JD, Pham G, Sridharan A, Khoury R, Wang YM, Hudda Z, Wilhelm J, Lichtenstein DA, Heyenbruch D, Cancelas JA, Davies SM, Lutzko C, Grimley MS.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cidofovir

Drugs, 1996
Cidofovir is a nucleotide analogue which inhibits viral DNA polymerase and is effective against human cytomegalovirus (CMV) infection. It is phosphorylated to its active form by cellular enzymes. With the long intracellular half-life of its metabolites, cidofovir can be administered weekly during induction and every other week during maintenance ...
A P, Lea, H M, Bryson
openaire   +3 more sources

Cidofovir

Archives of Ophthalmology, 1997
  +6 more sources

Cidofovir

Reactions Weekly, 2022
Michelle C. Simpson, Eric G. Schaefer
  +4 more sources